Remove Presentation Remove Treatment Remove Trials
article thumbnail

Transforming cancer treatment for greatest impact

Drug Target Review

Could you provide insights into the driving factors behind exploring novel treatments for cancer types? Additionally, in evaluating the effectiveness of our initial pipeline asset, we sought tumours suitable for intratumoural injection that present surface-accessible lesions. What aspects prompted this research direction?

Treatment 105
article thumbnail

Including Patients with Borderline Personality Disorder in Clinical Trials

Conversations in Drug Development Trends

By: Christine Moore, PhD, Vice President, Neuroscience, Scientific Solutions Patients with borderline personality disorder (BPD) face a heightened risk of substance abuse and suicide, as well as substantial delays in receiving treatment.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

New targeted therapies show promise in lung cancer treatment

Drug Target Review

These types differ in their etiology, natural history, and present distinct challenges in disease management. 2 Unmet needs in lung cancer treatment Recent decades have seen significant advancements in lung cancer treatment, especially with the introduction of targeted therapies and immunotherapies, which have notably improved survival rates.

article thumbnail

Breakthrough for pancreatic cancer treatment

Drug Target Review

1 Although pancreatic cancer is rarer than the abovementioned cancers, it claims over 50,000 lives each year in the United States because of a lack of effective treatments. Since then, two therapies have been approved for use in lung and breast cancer but it did not advance pancreatic cancer treatment.

article thumbnail

Leveraging Genetic Testing for Enrolling Rare Disease Trials

Conversations in Drug Development Trends

Written By: Derek Ansel, MS, CCRA, Executive Director, Therapeutic Strategy Lead, Rare Disease Given that 80% of rare diseases have a genetic etiology, genetic implications should be addressed at the onset of a clinical program to support trial enrollment. One diagnostic example that I discussed in my presentation is autism.

Trials 75
article thumbnail

Shifting Paradigms in PAH Clinical Trials: 7 Key Takeaways for Success

PPD

Though they do positively impact patients’ quality of life and hemodynamic parameters, these treatments — prostacyclin analogs and receptor agonists, phosphodiesterase 5 inhibitors, endothelin-receptor antagonists, and cGMP activators — have shown limited beneficial effects on survival and disease progression.

article thumbnail

The Next Generation of Vaccine Mega Trials

PPD

In the realm of vaccine development, mega trials — studies enrolling 5,000 subjects or more — have been instrumental in the fight against many pathogens, including influenza, rotavirus, malaria, RSV and most recently in the rapid development of vaccines against COVID-19.

Vaccine 96